Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (March 2025)
31 slides from Cantargia Ab's investor presentation, March 2025
Slide 1: Blocking the RIGHT signals to reduce disease severity
Blocking the RIGHT signals to reduce disease severity Corporate Presentation March 2025 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Global leader in IL1RAP antibody development
Cantargia – Global leader in IL1RAP antibody development NOVEL IL1RAP ANTIBODIES: BROADLY APPLICABLE TO TREAT INFLAMMATORY DISEASES & CANCER • IL1RAP signaling drives various autoimmune and inflammatory diseases • IL1RAP elevated in most solid and liquid tumors CAN10: OPPORTUNITY IN AUTOIMMUNITY/INF
Slide 4: Clinical Programs supported by Unique Platform
Clinical Programs supported by Unique Platform Asset Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 CAN10 Hidradenitis Suppurativa (HS) PDAC** Nadunolimab NSCLC** TNBC* New development programs CANxx through unique IL1RAP platform (e.g. BsMAb, ADC) PDAC – pancreatic cancer; NSCLC – non-sma
Slide 5: Management Team
Management Team Damian Marron Patrik Renblad David Liberg CEO CFO CSO Ton Berkien Dominique Tersago CBO CMO 5
Slide 6: CAN10 Opportunities in Autoimmune/Inflammatory Diseases
CAN10 OPPORTUNITIES IN AUTOIMMUNE/INFLAMMATORY DISEASES CAN10 is an Anti-IL1RAP antibody for treatment of autoimmune and inflammatory disease. CAN10 can, by binding IL1RAP, block IL-1, IL-33 and IL-36 signaling pathways simultaneously. This unique function provides CAN10 with great potential for the
Slide 7: CAN10 provides a unique opportunity to block IL-1 family signaling
CAN10 provides a unique opportunity to block IL-1 family signaling Joints • Osteoarthritis • Rheumatoid arthritis • Gout • The IL-1 family of ligands and receptors is primarily associated with acute and chronic inflammation¹ Skin Intestine • Hidradenitis • Crohn's disease Suppurativa (HS) Ulcerative
Slide 8: CAN10 is developed to block IL-1 family with precision
CAN10 is developed to block IL-1 family with precision • CAN10 blocks multiple IL-1 family signaling by targeting a single receptor – Binds crucial epitope on common accessory protein (IL1RAP) – Prevents signaling from IL-1α/β, IL-33 and IL- 36α/β/γ IL-1/33/36 cytokine mix • CAN10 has shown robust e
Slide 9: First-in-Human study – SAD/MAD
First-in-Human study – SAD/MAD MAD – Healthy (SC) • Healthy volunteers • 2 dose cohorts • Q2 2025: Phase 1 • Phase 2 preparations SAD (IV) • Q4 2025: Start Phase 2 • Healthy volunteers (N=76) • Cohorts: CAN10 (6), Placebo (2) MAD – Psoriasis (SC) • 10 dose cohorts • Finalized • Mild-Moderate plaque
Slide 10: CAN10 first-in-human study - SAD part
CAN10 first-in-human study - SAD part* Results – PD effects • Receptor occupancy documented (at Cmax) • Inhibition of IL-36 signaling documented at Cmax and day 8 → long lasting effect Receptor Occupancy Whole blood ex vivo inhibition assay Receptor IL-36 Occupancy Classical monocytes induced IL-6 r
Slide 11: Full blockade of IL-1β signaling at Cmax and Day 8
Full blockade of IL-1β signaling at Cmax and Day 8 IL-1β induced IL-6 release 3 fold change vs pre-dose IL-1β induced IL-6 2 1 • Unique function of CAN10 and differentiating from 0 approved treatments D1 D8 D1 D8 – Making immune cell non-responsive to IL-1 and IL-36 SAD9 Presumed placebo SUCCESSFULL
Slide 12: CAN10 First-in-Human study - MAD
CAN10 First-in-Human study - MAD Imiquimod-induced • Strong rational for IL1RAP blockade in inflammatory skin skin inflammation diseases 6 Total score (0-8) – Blocks skin inflammation and IL-17 where anti-IL-1β does Vehicle 4 not Ctrl Anti-IL-1β Anti-IL-1β Ctrl mCAN10 • Psoriasis chosen for phase 1
Slide 13: Hidradenitis Suppurativa (HS) – Disease Overview
Hidradenitis Suppurativa (HS) – Disease Overview Of people worldwide have Hidradenitis ~ 1-2%¹ 80-160 million people Suppurativa Of patients moderate/severe HS (Hurley stage ~ 50%² II/III) Of HS Patients are not well controlled on current ~ 55%³ SoC: TNFα & IL-17 Standard Of Care Time that patients
Slide 14: Unique MoA in the treatment of HS
Unique MoA in the treatment of HS IL-1 family has roles integrated with and in parallel to the IL-17 pathway • IL-1 family cytokines are jointly upregulated in HS skin “Spesolimab functionality” “Lutikizumab functionality” lesions • Unique CAN10 MoA differentiates from current treatments and create
Slide 15: CAN10 is validated by External clinical results in HS
CAN10 is validated by External clinical results in HS Spesolimab Spesolimab 100 10 Draining Tunnel count IL-36R-blockade (spesolimab) positive results on disease severity1 Change in IHS4 5 (%change) 50 • Efficacy in Phase 2 randomized controlled study: iHS4 and HASI-R, 0 with a particular effect on
Slide 16: Next: Proposed Phase 2 study in HS
Next: Proposed Phase 2 study in HS CAN10 dose 1 • N = ~40 pts per active arm, CAN10 dose 2 N = ~40-60 in placebo 3-months extension period • All-comers, with a set CAN10 dose 3 number of patients Placebo previously failing TNFα or IL-17 blockade 16 weeks • ~50 EU/US sites Primary Endpoint Patient po
Slide 17: Nadunolimab
NADUNOLIMAB COMBAT CANCER AND ENHANCE THE IMMUNE SYSTEM'S ABILITY TO DESTROY CANCER CELLS Nadunolimab (CAN04) is an Anti-IL1RAP antibody for treatment of various cancer types. CAN04 binds strongly to its target molecule IL1RAP, expressed on tumor cells from many types of cancer. CAN04 blocks the sig
Slide 18: IL1RAP overexpressed in most solid tumors provides treatment opportunity
IL1RAP overexpressed in most solid tumors provides treatment opportunity in various cancer types IL1RAP EXPRESSION IN SOLID TUMOR TYPES INCIDENCE RATES SHOW BROAD OPPORTUNITY IN VARIOUS CANCER TYPES 100% IL1RAP-expressing tumors 75% 50% 25% 0% C ic st al er al CC er SCL eat r ea ect Liv ge S dd a N
Slide 19: Pancreatic Cancer (PDAC) as primary indication
Pancreatic Cancer (PDAC) as primary indication Stage IV - Stage III - locally metastatic advanced Stage III Stage IV 130.000 patients* LOCALLY ADVANCED OR METASTATIC DISEASE Survival: → 8.5 – 11.1 mo Treatment: → Gemcitabine/nab-paclitaxel → Gemcitabine if poorer performance → FOLFIRINOX only if goo
Slide 20: Pancreatic Cancer – Positive data in 1st line patients
Pancreatic Cancer – Positive data in 1st line patients OS and iPFS for mITT patients Best responses according to iRECIST 50% Best change in tumor size 0% -50% -100% iCPD iUPD iSD iPR Nadunolimab combination with Gem/Abraxane in 1st line PDAC (n=73): → 33% response rate with long OS and iPFS → Additi
Slide 21: High IL1RAP expression is linked to poor outcome in pancreatic tumors
High IL1RAP expression is linked to poor outcome in patients with pancreatic tumors → IL1 family members are upregulated in PDAC tumors as compared to normal pancreatic tissue → IL1RAP is expressed on tumor cells, cancer- associated fibroblasts and immune cells in tumor microenvironment Protein Atla
Slide 22: PDAC: Strong efficacy in patients with high tumor IL1RAP expression
PDAC: Strong efficacy in patients with high tumor IL1RAP expression level OS by IL1RAP subgroup IL1RAP High IL1RAP Low 50% Best change in tumor size 0% iCPD iUPD iSD -50% iPR -100% Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDAC patients → High IL1RAP expression is a poor prognost
Slide 23: Strong efficacy reflected in “IL1RAP high” patients
Strong efficacy reflected in “IL1RAP high” patients iPFS by IL1RAP subgroup OS by IL1RAP subgroup Monotherapy efficacy analysis for IL1RAP High (n=5) vs IL1RAP Low (n=12) PDAC patients (late- stage, typically progressed after two lines of chemotherapy): → Significantly prolonged iPFS in IL1RAP High
Slide 24: PDAC – Manageable safety and supports MOA
PDAC – Manageable safety and supports MOA → Neutropenia manageable through G-CSF prophylaxis → In 7 patients given G-CSF prophylaxis, only 1 developed grade 3-4 neutropenia → Only 1 % peripheral neuropathy grade 3-4 observed (17% in historical controls) Gem/Abraxane Nadunolimab+Gem/Abraxane Grade 3
Slide 25: PDAC – Next steps
PDAC – Next steps Feasibility Assay development; selection of one clone, one • Metastatic PDAC patients selected for platform and one protocol high IL1RAP expression • Treatment naive patients • Combination with gemcitabine/nab- paclitaxel Validation Assay validation; enable patient • Controlled stu
Slide 26: NSCLC – Strongest effects in patients no longer responding to PD(L)-1
NSCLC – Strongest effects in patients no longer responding to PD(L)-1 SHOW VERY STRONG DATA IN 2ND LINE NON-SQ NSCLC - HIGH UNMET MEDICAL NEED Note: subgroup analysis from 40 patients 28
Slide 27: Triple-negative breast cancer (TNBC)
Triple-negative breast cancer (TNBC) Promising early safety and efficacy Nadunolimab combination with Gem/Carbo in 1st/2nd line metastatic TNBC: Best responses according to RECIST OS and PFS 100% 15 patients enrolled in the dose- escalation phase: Best change in tumor size 50% • Preliminary ORR: 60%
Slide 28: Milestones & Investment Highlights
MILESTONES & INVESTMENT HIGHLIGHTS
Slide 29: Investment Highlights
Investment Highlights CORPORATE STRENGTH DRIVING INNOVATION • Dedicated Team with experience from Pharma, Biotech & Academia • Two clinical programs ongoing • CANxx Technology Platform (ADC + Bi-Specific mAb: Worldclass Leader in IL1RAP antibody development CAN10: STRONG PHASE 1 DATA – NEXT PRIORITI
Slide 30: Upcoming milestones
Upcoming milestones 2025 Q1 Q2 Q3 Q4 PDAC Regulatory Update TRIFOUR recruitment Nadunolimab TNBC completed TRIFOUR initial results Study start with AML DoD/MD Anderson* Initial Phase 1 MAD Phase 1 MAD study Phase 2 start in CAN10 results completed Hidradenitis Suppurativa Other Additional new precli
Slide 31: Thank you
Thank you Contact details: Damian Marron Chief Executive Officer damian.marron@cantargia.com Patrik Renblad Chief Financial Officer patrik.renblad@cantargia.com